CPEX Pharmaceuticals, Inc. is a specialty pharmaceutical company in the business of development, licensing and commercialization of pharmaceutical products utilizing its validated drug delivery technology. The Company’s platform drug delivery technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through formulation development with molecules, such as CPE-215. It has licensed an application of its CPE-215 drug delivery technology to Auxilium, which led to the launch of Testim in the United States. The Company’s research and development programs for its drug delivery technologies are primarily focused on the development of Nasulin, its intranasal insulin product candidate. It has completed two Phase II A studies for Nasulin in patients with Type 1 diabetes patients using its CPE-215 technology, one in the United States and one in India.